Update on AZD7442 STORM CHASER Trial in Post-Exposure Prevention of Symptomatic COVID-19

15 June 2021 -- AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials